BIG Summit: Experts see signs of M&A momentum in 2026
We could be in for another big year of biotech M&A. A busy 2025, in both licensing and M&A in biopharma, saw over 4,000 […]
BIG Summit: Experts see signs of M&A momentum in 2026 Read More »
Federal Policy
BIO Patient Advocacy Coffee Chat: Act now to be heard on CMS drug pricing
The Medicare drug price “negotiation” process has entered its third year, with some evolution but continued complexity for patients and patient organizations. This year,
BIO Patient Advocacy Coffee Chat: Act now to be heard on CMS drug pricing Read More »
BIO Coffee Chat: MFN proposals would harm innovation and access
Most Favored Nation (MFN) type drug pricing proposals that were proposed by the Centers for Medicare & Medicaid Innovation (CMMI) in December 2025 would
BIO Coffee Chat: MFN proposals would harm innovation and access Read More »
BIO CEO testifies in hearing highlighting PBMs’ impact on drug prices
Pharmacy benefit managers (PBMs) were identified as a major driver behind higher prescription drug costs in a congressional hearing that featured testimony from BIO
BIO CEO testifies in hearing highlighting PBMs’ impact on drug prices Read More »
NIH Director says no studies link vaccines and autism in hearing on modernization
National Institutes of Health (NIH) Director Jay Bhattacharya acknowledged there are no studies indicating a link between any vaccine and autism as Senators pushed
NIH Director says no studies link vaccines and autism in hearing on modernization Read More »
BIO lauds passage of PPRV reauthorization and legislation on PBM reform
The Biotechnology Innovation Organization (BIO) hailed inclusion of a bill to encourage new treatments for children with rare diseases and measures targeting reform of
BIO lauds passage of PPRV reauthorization and legislation on PBM reform Read More »
BIO tells Congress how to maintain US biotech leadership
Maintaining a world-leading biotech industry keeps Americans safer and its economy stronger. Appropriate federal actions can support this leadership, the Biotechnology Innovation Organization (BIO)
BIO tells Congress how to maintain US biotech leadership Read More »
Using AI In patent practice: Practical and ethical issues
The use of AI tools in the workplace is on the rise. This trend is equally true in the arena of patent practice. However,
Using AI In patent practice: Practical and ethical issues Read More »
BIO IP Conference looks at academics and perceptions of IP
The post-COVID era has been especially hard on patent lawyers working in the biopharma space. “I don’t think it’s an accident that during the
BIO IP Conference looks at academics and perceptions of IP Read More »
Patient advocates urge action on PPRV to help fight rare disease
Patient advocates retold emotional stories of lives saved, changed—or at risk—as they discussed one of the most important factors enabling breakthroughs in fighting rare
Patient advocates urge action on PPRV to help fight rare disease Read More »